Navigation Links
SynCo Bio Partners Expands the Class A Zone in its Aseptic Filling Facility
Date:8/4/2011

AMSTERDAM, The Netherlands, August 4, 2011 /PRNewswire/ --

SynCo Bio Partners B.V., one of the leading GMP contract manufacturers of biopharmaceuticals today announced that its aseptic filling facility is again fully operational and SynCo has produced and released the first drug product batches for its clients after the expansion of its Class A zone.  

The expansion of the Class A zone is an important milestone in SynCo's strategy in supporting its clients with new product launches in the US and the rest of the world.  SynCo's aseptic filling facility is able to fill and lyophilize a wide range of biopharmaceuticals which include proteins, monoclonal antibodies, polysaccharides, nucleic acids, aluminium containing vaccines, RNA and live biotherapeutics for clinical and market supply.

Announcing this upgrade, Pierre Warffemius, CEO of SynCo Bio Partners said:

"The expansion of the Class A zone is an excellent addition to SynCo Bio Partners' already state-of-the-art contract manufacturing facility in Amsterdam. SynCo is one of the few biopharmaceutical CMOs in the world with a recognized track record in both clinical and commercial manufacturing of both bulk drug substance and drug product and continuously invests in its facilities to achieve its goal: Trust us to make it right."

About SynCo Bio Partners B.V.

SynCo Bio Partners B.V. is a biopharmaceutical GMP Contract Manufacturing Organization located in Amsterdam, The Netherlands, licensed for clinical and commercial GMP manufacturing of Bulk Drug Substances and Drug Products.  As a truly global player, SynCo offers a fully integrated range of biopharmaceutical development and manufacturing services supporting small biotech to large pharmaceutical organizations worldwide from the earliest stages in process development, through pre-clinical and clinical trials, biologic license approval and market supply. For more information, please visit
'/>"/>

SOURCE SynCo Bio Partners B.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
2. SynCo Bio Partners and Versartis Expand Collaboration as Lead Product Enters into Clinical Trials
3. SynCo Bio Partners Signs New Manufacturing Agreements to Supply the US Market; Securing its Position as a Market Leader in Microbial Biopharmaceutical Contract Production
4. SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company
5. SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes
6. SynCo Bio Partners Increases its Capacities by Expanding its Quality Team
7. SynCo Bio Partners Wins Best Contract Manufacturing Organization 2009 ViE Award
8. INC Research and Debiopharm Group(TM) Announce Strategic Partnership
9. Hitachi partnership brings new tools and electron microscope reference center to Edmonton
10. Emerson Ecologics Expands Partnership With Metagenics, Announces National Distribution Agreement
11. HCCS Partners with American Association of Critical Care Nurses (AACN) to Offer Nurse Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Bio-Techne Corporation (NASDAQ: TECH ) announced today ... serve in a newly created position of Senior Vice ... be responsible for managing the operations of Bio-Techne,s Protein ... in July 2014 and the recently acquired CyVek business. ... ProteinSimple develops and commercializes proprietary systems and consumables that ...
(Date:11/24/2014)...  IGI Laboratories, Inc. (NYSE MKT: IG), a ... company, today announced it has submitted an additional abbreviated ... Drug Administration (FDA), which brings the Company,s total number ... submissions now pending at the FDA. ... Company, commented, "Our team here at IGI has continued ...
(Date:11/24/2014)... 24, 2014 VolitionRx Limited (OTCQB: VNRX), ... cancer and other conditions, today announced that data from its ... for Business BioWin Day 2014, being held November 26, 2014 ... from VolitionRx,s lung cancer pilot study, the samples for which ... Universitaire (CHU) de Liege in Belgium . ...
(Date:11/24/2014)... November 23, 2014 One of the most ... optics and photonics is now available to high school and ... cost. SPIE, the international society for optics and photonics ... complete SPIE Digital Library available to high schools ... “Light-based technologies are integral to all areas of life in ...
Breaking Biology Technology:Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3IGI Laboratories, Inc. Announces ANDA Submission 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6SPIE Digital Library Now Available to High Schools, Two-Year Colleges at No or Low Cost 2
... Business and technology opportunities are affording today,s ... decades ago—the chance to create successful new companies ... leaders who will speak at Keck Graduate Institute ... of KGI,s Focus Track Fridays seminar series, executives ...
... Pharmasset, Inc. (Nasdaq: VRUS ), a ... commercializing novel drugs to treat viral infections, today reported ... ended September 30, 2011. At fiscal year end Pharmasset ... used $21.7 million of our cash and cash equivalents ...
... inVentiv Health, Inc., offering best-in-class clinical, commercial ... today that it has been selected by the ... operations support, as well as recruiting and sales ... for Type 2 diabetes. inVentiv ...
Cached Biology Technology:'Garage' Start-ups Now Possible in Life Sciences Industry 2Pharmasset Reports Fiscal Year End 2011 Financial Results 2Pharmasset Reports Fiscal Year End 2011 Financial Results 3Pharmasset Reports Fiscal Year End 2011 Financial Results 4Pharmasset Reports Fiscal Year End 2011 Financial Results 5Pharmasset Reports Fiscal Year End 2011 Financial Results 6Pharmasset Reports Fiscal Year End 2011 Financial Results 7Pharmasset Reports Fiscal Year End 2011 Financial Results 8inVentiv Health Selected to Provide Sales Operations Support for Santarus 2inVentiv Health Selected to Provide Sales Operations Support for Santarus 3inVentiv Health Selected to Provide Sales Operations Support for Santarus 4
(Date:11/5/2014)... professor of biology in the UTSA College of ... nation selected to receive a two-year $300,00 National ... Research (EAGER). The funding supports President Obama,s BRAIN ... create new technology that will demystify complex brain ... in neuroscience are broken into the interactions of ...
(Date:11/4/2014)... right amount of death at the right time might ... new research that could help in understanding animal populations, ... In a paper in the journal Trends in ... European colleagues conclude that the kind of positive population ... individuals, or mortality, depends on the size and developmental ...
(Date:11/4/2014)... England , November 4, 2014 ... and vertical market growth   Fuel3D , ... has closed a funding round totaling $6.4 million (£4 million). ... million) funding secured earlier this year and paves the way ... in 2015. The funding round was led by ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3When less is more: Death in moderation boosts population density in nature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... such as Alzheimer,s disease, Parkinson,s disease, and amyotrophic ... for patients, put a tremendous burden on family ... The most consistent risk factor for developing ... increase in life expectancy, the incidence of individuals ...
... 2008 On the day Americans elect a new president, ... at the University of Houston and outline the daunting global ... Trenberth, head of climate analysis at the National Center for ... manmade global warming at a colloquium Tuesday, Nov. 4. ...
... Although research has linked inbreeding with elevated rates of ... study finds it plays no part in the high ... recently examined 2,000 adult and juvenile salamanders and found ... missing, extra or dwarfed digits (equivalent to fingers and ...
Cached Biology News:3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions 2Climate change expert to discuss grim global warming predictions 2Study rules out inbreeding as cause of amphibian deformities 2
... state-of-the-art separation system using the asymmetric flow ... integrates easily with Wyatts multi-angle light scattering ... as the Optilab DSP. The combined system ... of the particles/molecules separated by the AFFF ...
Monoclonal antibodies conjugated with rhodamine...
... Both compact and lightweight, the Moticam ... microscope through the eyepiece, eyetube, or trinocular ... easy to use Plug-and-Play Images 2.0ML software ... Image manipulation tools to maximize resolution for ...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
Biology Products: